Increasing B-Type Natriuretic Peptide Levels Predict Mortality in Unselected Haemodialysis Patients
Open Access
- 1 August 2011
- journal article
- Published by Oxford University Press (OUP) in European Journal of Heart Failure
- Vol. 13 (8) , 860-867
Abstract
Aims Cardiac disease is the major cause of death in patients undergoing chronic haemodialysis. Recent studies have found that B‐type natriuretic peptide (BNP) levels accurately reflect the cardiovascular burden of dialysis patients. However, the prognostic potential of BNP measurements in dialysis patients remains unknown. Methods and results The study included 113 chronic dialysis patients who were prospectively followed up. Levels of BNP were measured at baseline and every 6 months thereafter. The potential of baseline BNP and annual BNP changes to predict all‐cause and cardiac mortality were assessed as endpoints. Median follow‐up was 735 (354–1459) days; 35 (31%) patients died, 17 (15%) of them from cardiac causes. Baseline BNP levels were similar among survivors and non‐survivors, and failed to predict all‐cause and cardiac death. Cardiac death was preceded by a marked increase in BNP levels. In survivors BNP levels remained stable [median change: +175% (+20–+384%) vs. −14% (−35–+35%) over the 18 months preceding either death or the end of follow‐up, P< 0.001]. Hence, annual BNP changes adequately predicted all‐cause and cardiac death in the subsequent year {AUCall‐cause = 0.70 [SD 0.05, 95% CI (0.60–0.81)]; AUCcardiac = 0.82 [SD 0.04, 95%CI (0.73–0.90)]}. A BNP increase of 40% provided the best cut‐off level. Cox regression analysis confirmed that annual increases over 40% were associated with a seven‐fold increased risk for all‐cause and cardiac death. Conclusions Annual BNP increases above 40% predicted all‐cause and cardiac death in the subsequent year. Hence, serially measuring BNP levels may present a novel tool for risk stratification and treatment guidance of end‐stage renal disease patients on chronic dialysis.Keywords
This publication has 29 references indexed in Scilit:
- Natriuretic peptides in heart failure: should therapy be guided by BNP levels?Nature Reviews Cardiology, 2009
- Hemodialysis-Induced Cardiac InjuryClinical Journal of the American Society of Nephrology, 2009
- Rosuvastatin and Cardiovascular Events in Patients Undergoing HemodialysisNew England Journal of Medicine, 2009
- Predictive Role of BNP and NT-proBNP in Hemodialysis PatientsNephron Clinical Practice, 2008
- Change in N-terminal-pro-B-type-natriuretic-peptide and the risk of sudden death, stroke, myocardial infarction, and all-cause mortality in diabetic dialysis patientsEuropean Heart Journal, 2008
- Carvedilol Reduces Elevated B-type Natriuretic Peptide in Dialyzed Patients Without Heart Failure: Cardioprotective Effect of the β-blockerJournal of Cardiovascular Pharmacology, 2007
- Daily dialyses decrease plasma levels of brain natriuretic peptide (BNP), a biomarker of left ventricular dysfunctionHemodialysis International, 2006
- Effect of Telmisartan on Ambulatory Blood Pressure Monitoring, Plasma Brain Natriuretic Peptide, and Oxidative Status of Serum Albumin in Hemodialysis PatientsHypertension Research, 2005
- Beneficial effect of β-adrenergic blockade on left ventricular function in haemodialysis patientsClinical Science, 2001
- Comparison of Mortality in All Patients on Dialysis, Patients on Dialysis Awaiting Transplantation, and Recipients of a First Cadaveric TransplantNew England Journal of Medicine, 1999